EcoDrugPlus

Prostaglandin D2 Receptor 2

Ensembl ID : ENSPNAG00000015054
Gene Symbol: PTGDR2
4 Cross references
145 Possible Orthologues:

Prostaglandin E Receptor 1a (Subtype Ep1)

Ensembl ID : ENSPNAG00000008757
Gene Symbol: PTGER1A
1 Cross references
167 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSPNAG00000012020
Gene Symbol: PTGER3
3 Cross references
195 Possible Orthologues:

Prostaglandin E Receptor 4

Ensembl ID : ENSPNAG00000021508
Gene Symbol: PTGER4
3 Cross references
201 Possible Orthologues:

Prostaglandin E2 Receptor Ep1 Subtype-Like

Ensembl ID : ENSPNAG00000000846
Gene Symbol: LOC108432074
3 Cross references
164 Possible Orthologues:

Prostaglandin E2 Receptor Ep2 Subtype-Like

Ensembl ID : ENSPNAG00000013858
Gene Symbol: LOC108441867
3 Cross references
202 Possible Orthologues:

Prostaglandin E2 Receptor Ep2 Subtype-Like

Ensembl ID : ENSPNAG00000027306
Gene Symbol: LOC108412689
3 Cross references
170 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSPNAG00000007992
Gene Symbol: LOC108430308
3 Cross references
202 Possible Orthologues:

Prostaglandin F2-Alpha Receptor-Like

Ensembl ID : ENSPNAG00000012814
Gene Symbol: LOC108438684
3 Cross references
195 Possible Orthologues:

Prostaglandin G/h Synthase 2-Like

Ensembl ID : ENSPNAG00000016905
Gene Symbol: LOC108442416
3 Cross references
209 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSPNAG00000009713
Gene Symbol: PTGIR
3 Cross references
187 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSPNAG00000005508
Gene Symbol: PTGS1
3 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).